clinical trial · NCT04603495
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPelabresibRuxolitinibPlacebo
brief summary
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
started
Apr 9, 2021
primary completion
Aug 23, 2023
completion
Jun 30, 2027
last updated
Dec 17, 2025
official title
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol